# RELOVAIR® Lung Deflation Study

> **NCT01691885** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 45 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Furoate
- **DRUG:** Vilanterol

## Key facts

- **NCT ID:** NCT01691885
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691885, "RELOVAIR® Lung Deflation Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01691885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*